| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| Targets |
Anti-Tuberculosis; bacterial ATP synthase
|
|---|---|
| ln Vitro |
The recently synthesized pyrrole Sudoterb (LL3858) (Fig. 3) showed higher bactericidal activity compared to isoniazid. Sudoterb is active against M. tuberculosis strains that are resistant to available anti-TB drugs [1].
Basic biology information [3] Drug target/mechanism: Not known; Sudoterb (LL3858) is a pyrrole derivative In-vitro potency against MTB: M. tuberculosis MIC: 0.12 0.025 mg/ml. Other in-vitro activity: The compound demonstrates in vitro synergy with rifampin. It is bactericidal in 12 days with concentration-dependent killing. Other pyrroles have shown activity against TB. |
| ln Vivo |
The effectiveness of Sudoterb (LL3858) (12.5 mg/kg and 25 mg/kg, sidewall, 4 and 8 weeks) against M. mice infected with TB [2]. The mouse oral drug sudoterb has an LD50 of 700 mg/kg [2].
In-vivo efficacy in animal model: In mouse models of 12 weeks duration 12.5 mg/kg Sudoterb (LL3858) showed good efficacy and complete clearance from lung and spleen not seen with the other compounds tested. No relapse was observed up to 2 months following the final dose.[3] Efficacy in humans Web releases (for example Media coverage summary 7 2004) indicate that clinical trials may begin but the Lupin website does not post any further information on this compound [3]. |
| Enzyme Assay |
Preliminary in vitro antitubercular screening [1]
MIC of the selected compounds 3a–c, 3f–k, 4a–d, 5, 6 and 7 were subjected to antimycobacterial evaluation against M. tuberculosis H37Ra 7131 strain in liquid medium by the broth dilution method according to modified method of Heifets. |
| ADME/Pharmacokinetics |
PK in mice is better than with INH in terms of halflife, Cmax and AUC. [3]
|
| References |
[1]. Synthesis and anti-mycobacterial evaluation of some new isonicotinylhydrazide analogues. Bulletin of Faculty of Pharmacy, Cairo University. 2015, 53 (1), 45-52
[2]. In search of new cures for tuberculosis. Med Chem. 2007 May;3(3):301-16. [3]. LL-3858. Tuberculosis (Edinb) . 2008 Mar;88(2):126. |
| Additional Infomation |
The last 10 years have seen resurgent industry activity in discovery and development of new drugs for the treatment of tuberculosis (TB), a growing widespread and devastating (more than 2 million deaths annually) bacterial infection that is of increasing concern in developing and developed nations alike. This review describes drugs currently being evaluated in the clinic for treatment of uncomplicated and drug resistant pulmonary TB, and updates the literature on 5 new drugs that entered clinical trials in the last 4 years.[2]
The synthesis of some new 3,4-disubstituted thiazolylideneisonicotinohydrazide derivatives 3a–k, 2-substituted thiazolidinylisonicotinamide derivatives 4a–d and pyrrolylisonicotinamide derivatives 5, 6 and 7 is described. The resulted compounds are evaluated for their in vitro antitubercular activity. The minimum inhibitory concentration (MIC) of compound 3g showed comparable in vitro activity to isoniazid against Mycobacterium tuberculosis H37Ra 7131 strain in concentration 9.77 μg/mL.[3] |
| Molecular Formula |
C29H30CL2F3N5O
|
|---|---|
| Molecular Weight |
592.4882
|
| Exact Mass |
591.178
|
| CAS # |
1044503-04-9
|
| Related CAS # |
Sudoterb;676266-31-2
|
| PubChem CID |
71587914
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
7.263
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
40
|
| Complexity |
762
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=C(C=C(C2=CC=CC=C2)N1NC(=O)C3=CC=NC=C3)CN4CCN(CC4)C5=CC=CC(=C5)C(F)(F)F.Cl.Cl
|
| InChi Key |
FVWAUSWEYDJAAM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C29H28F3N5O.2ClH/c1-21-24(20-35-14-16-36(17-15-35)26-9-5-8-25(19-26)29(30,31)32)18-27(22-6-3-2-4-7-22)37(21)34-28(38)23-10-12-33-13-11-23/h2-13,18-19H,14-17,20H2,1H3,(H,34,38)2*1H
|
| Chemical Name |
N-(2-methyl-5-phenyl-3-((4-(3-(trifluoromethyl)phenyl)piperazin-1-yl)methyl)-1H-pyrrol-1-yl)isonicotinamide dihydrochloride
|
| Synonyms |
LL3858 HCl; LL3858 dihydrchloride; Sudoterb dihydrochloride; 1044503-04-9; UNII-5DRV9UU348; 5DRV9UU348; LL-3858; LL 3858.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6878 mL | 8.4390 mL | 16.8779 mL | |
| 5 mM | 0.3376 mL | 1.6878 mL | 3.3756 mL | |
| 10 mM | 0.1688 mL | 0.8439 mL | 1.6878 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
